Literature DB >> 10503683

Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment.

B Schiller1, G Elinder.   

Abstract

The possible use of inflammatory parameters as a predictor of coronary artery lesions (CAL) and the effect of intravenous immunoglobulin (IVIG) treatment in 30 Swedish children with acute Kawasaki disease were investigated. All the patients were treated with IVIG (2 g/kg) and seven of them had CAL. Ten febrile children, hospitalized for treatment of severe infection, and 15 healthy children served as controls. The levels of soluble E-selectin and soluble intercellular adhesion molecule (ICAM)-1 in the Kawasaki patients were elevated in comparison to healthy, but not in comparison to febrile controls. Paired analysis of our patients before and after IVIG therapy during acute disease revealed lowered levels of C-reactive protein, interleukin-6, soluble E-selectin and soluble ICAM-1. We found no statistically significant relationships among any of these parameters as a possible predictor of CAL, but three patients with cardiac sequelae demonstrated high values for these inflammatory parameters. These findings may reflect endothelial activation in connection with vasculitis, and the anti-inflammatory effect of IVIG treatment lowering cytokine levels and subsequently decreasing the expression and shedding of adhesion molecules. In conclusion, we were unable to identify a predictor of CAL in the acute phase. The patients had higher levels of soluble E-selectin and soluble ICAM-1 than did afebrile controls, but not febrile controls. The patients' levels of C-reactive protein, interleukin-6, soluble E-selectin and soluble ICAM-1 were decreased after 1-2d of IVIG treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10503683     DOI: 10.1080/08035259950168766

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease.

Authors:  Beth F Printz; Lynn A Sleeper; Jane W Newburger; L LuAnn Minich; Timothy Bradley; Meryl S Cohen; Deborah Frank; Jennifer S Li; Renee Margossian; Girish Shirali; Masato Takahashi; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

Review 2.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Authors:  M Gupta; G J Noel; M Schaefer; D Friedman; J Bussel; R Johann-Liang
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

Review 4.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases.

Authors:  M H Biezeveld; G van Mierlo; R Lutter; I M Kuipers; T Dekker; C E Hack; J W Newburger; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  BTNL2 gene polymorphisms may be associated with susceptibility to Kawasaki disease and formation of coronary artery lesions in Taiwanese children.

Authors:  Kai-Chung Hsueh; Ying-Ju Lin; Jeng-Sheng Chang; Lei Wan; Fuu-Jen Tsai
Journal:  Eur J Pediatr       Date:  2009-11-01       Impact factor: 3.183

7.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.